| Top Adding |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Real Estate > Homes > Lender Fraud - A Significant Factor in the Sub-Prime Lending Meltdown? |
|
Top Adding - Lender Fraud - A Significant Factor in the Sub-Prime Lending Meltdown?
Appraisers throughout southern California are currently discovering hundreds of fraudulent real estate transactions. These According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product transactions are all easy to spot because they're a matter of public record. The most common type of fraudulent transacti ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in n recently is the ISAC scheme (Inflated Sale and Crash). This type of scheme involves cash back at the time of closing to lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. third party. To accomplish this, the purchase price has been inflated 10 to 30% above market value. When this type of tr here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe nsaction has been perpetrated it is readily apparent, for example you'll see a property listed at $500,000 for several mont d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro s then sold with a final purchase price of $600,000, with no down payment. The seller is paying the difference, in this ca ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc se $100,000, to the buyer at closing. Now you may ask, "How can this be possible?" During the last year, with the number easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi f transactions occurring declining many lenders relaxed their standards for borrowers (no secondary review of appraisal). nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically his created an ideal environment in which these fraudulent transactions could thrive, since the key to these schemes is the and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ appraisal. Every one of these sales required a fraudulently inflated appraisal. Federal and state investigators have been ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi overwhelmed during the last 15 months due to the sheer number of these types of transactions. The primary parties involved ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a in these fraudulent sales are the selling agent, the appraiser, the buyer, and a third-party through whom the money is fun dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod eled. All of which will be subject to prosecution. In this type of investigation the listing agent and seller are also ty cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ically considered co-conspirators. When a transaction of this type closes, the buyer has achieved their objective (cash ba tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen k at closing). The end result of this is that once the transaction closes the buyer has no motivation to make any payments t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel on the property because they have no money invested. The loan quickly goes into default and the lender ends up foreclosing ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust on a home worth 10 to 30% less than the fraudulently appraised value. In conclusion, there are new schemes consistently p y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products pping up to take advantage of changes in the real estate market. There are many victims, not only the lender but people un . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de nowingly involved, as well as the stability of the real estate market and the communities in which these fraudulent schemes elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip have taken place. The only defense is knowledge and relationships with professionals you trust to make the right decisions tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Top 7 Tips on Selling a Franchised Business HughesNet Is The World's Leading Broadband Satellite Service For All Consumers Cheapest Loans: When Cheap Loans are Not Good Enough
|